VolitionRX Limited Common Stock (VNRX)

Frequently Asked Questions About VolitionRX Limited Common Stock (VNRX)

Has VolitionRX received any funding?

Yes, VolitionRX has secured funding through a combination of equity offerings, private placements, and strategic partnerships. This funding has enabled the company to expand its research capabilities, advance its product development, and support clinical trials necessary for bringing its diagnostic tests to market.

How can investors monitor VolitionRX's performance?

Investors can monitor VolitionRX's performance by following the company's financial reports, press releases, and updates available on its official website and through financial news outlets. Additionally, investors can track the stock's performance on the New York Stock Exchange under the ticker VNRX and engage with investor relations for insights into the company's progress and strategic direction.

How does VolitionRX differentiate itself from competitors?

VolitionRX differentiates itself from competitors by focusing exclusively on blood-based diagnostics using its proprietary Nu.Q™ technology, which offers a unique and innovative solution for cancer detection. Additionally, the company's commitment to affordability, ease of use, and rapid result delivery sets it apart in a market that increasingly values patient-centric healthcare solutions.

Is VolitionRX Limited publicly traded?

Yes, VolitionRX Limited is a publicly traded company listed on the New York Stock Exchange under the ticker symbol VNRX. Being publicly traded allows the company to access capital for its research and development activities and provides transparency to its investors regarding its financial performance and operational activities.

What are some current projects of VolitionRX?

VolitionRX is currently working on several projects that include the development of blood tests for colorectal cancer, prostate cancer, and other tumors, as well as validating and commercializing its tests in multiple global markets. The company is also engaged in ongoing clinical studies to assess the efficacy and reliability of its diagnostic tests.

What are VolitionRX's growth strategies?

VolitionRX's growth strategies include expanding its portfolio of cancer diagnostic tests, increasing its global market presence, forming strategic partnerships with healthcare organizations, and investing in ongoing research and development. The company aims to leverage its innovative technology to capture significant market share in the cancer diagnostics industry.

What challenges does VolitionRX face?

VolitionRX faces several challenges, including intense competition in the biotechnology and cancer diagnostics industry, the need for continuous R&D investment, and navigating regulatory hurdles to gain approvals for its diagnostic tests. Additionally, market acceptance of new diagnostic technologies can be slow, posing challenges to commercialization efforts.

What does VolitionRX Limited do?

VolitionRX Limited is a biotechnology company focused on the development of blood-based tests for the early detection of cancer. The company utilizes its proprietary Nu.Q™ technology platform to create simple, cost-effective, and non-invasive diagnostic tests that aid in cancer diagnosis and management. Their goal is to improve patient outcomes through early detection and effective monitoring of various cancers.

What is the company's approach to early cancer detection?

VolitionRX adopts a non-invasive approach to early cancer detection by utilizing blood tests that detect nucleosome-based biomarkers. This approach aims to facilitate early diagnosis and monitoring of cancer, ultimately leading to timely and potentially life-saving interventions. By simplifying the testing process, VolitionRX strives to make cancer screening more accessible and efficient.

What is the company's pipeline of products?

VolitionRX has a robust pipeline of products that includes various blood tests for the detection of different cancers. The company's current focus includes tests for colorectal cancer (Nu.Q™ Colorectal Cancer Test), prostate cancer, and potentially other cancers. The development pipeline reflects VolitionRX’s commitment to advancing cancer diagnostics and broadening its clinical applications.

What is the company's vision?

VolitionRX's vision is to revolutionize cancer diagnostics by making early detection through blood tests accessible and routine in clinical practice worldwide. The company aims to change the standard of care for cancer detection, ultimately leading to improved treatment outcomes and enhanced quality of life for patients diagnosed with cancer.

What is the Nu.Q™ technology?

The Nu.Q™ technology is VolitionRX's proprietary platform designed to detect cancer and other diseases through the analysis of nucleosomes released from cells into the bloodstream. By analyzing specific biomarkers in a blood sample, VolitionRX aims to provide clinicians with vital information that can lead to early diagnosis and treatment, thereby enhancing survival rates for patients.

What is the significance of early cancer detection?

Early cancer detection is significant because it can dramatically improve treatment outcomes and survival rates. When cancer is detected at an early stage, there are often more treatment options available, and patients generally experience a better prognosis. VolitionRX’s focus on developing affordable and accessible blood tests for early detection aims to facilitate timely interventions and improve overall healthcare outcomes.

What regulatory approvals has VolitionRX received?

VolitionRX has made progress in obtaining regulatory approvals for its diagnostic tests in various jurisdictions. The company is actively pursuing CE mark approval in Europe for its tests, as well as submissions for approvals in other regions, which are crucial for market entry and commercialization of its innovative blood tests.

What role do partnerships play in VolitionRX's growth?

Partnerships are crucial to VolitionRX's growth strategy, as they provide access to additional resources, expertise, and distribution networks. Collaborating with research institutions, healthcare providers, and other biotechnology firms enables VolitionRX to enhance its product offerings, accelerate its clinical studies, and expand its market presence effectively.

What types of cancer does VolitionRX focus on?

VolitionRX focuses on various types of cancer, including colorectal, prostate, breast, and other malignancies. The company's efforts are directed toward developing blood tests that can detect these cancers in their early stages, thereby increasing the chances of successful treatment and improving overall patient prognosis.

Where is VolitionRX Limited headquartered?

VolitionRX Limited is headquartered in Singapore, a strategic location that provides access to key markets and partnerships in the biotechnology and healthcare sectors. The company's international presence allows it to collaborate with esteemed research institutions and healthcare providers worldwide.

Who are the key people involved in VolitionRX?

VolitionRX's team includes a diverse group of professionals with expertise in cancer research, biotechnology, and business management. The company is led by a team of experienced executives and scientists, including CEO Cameron Reynolds and Chief Scientific Officer Dr. Jake M. McHome, who together drive the company’s strategic direction and innovation in cancer diagnostics.

What is the current price of VolitionRX Limited Common Stock?

The current price of VolitionRX Limited Common Stock is 0.4880

When was VolitionRX Limited Common Stock last traded?

The last trade of VolitionRX Limited Common Stock was at 8:00 pm EDT on April 11th, 2025